Compare Ginkgo Bioworks Holdings Inc (DNA) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.79. The key difference: Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| DNA | YMAG | |
|---|---|---|
Market Cap | $590.53M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $16.14 | $15.98 |
52-Week Low | $5.48 | $11.00 |
Enterprise Value | $627.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
YMAG trades at $11.70, down 0.93% on the day, with technical indicators showing a neutral overall signal. The ETF has demonstrated consistent weekly dividend distributions throughout 2026, with payouts ranging from $0.07 to $0.40 per share. Recent news highlights YMAG's strategy of bundling Magnificent Seven exposure through option income ETFs, though some analysts express concerns about NAV decay and limited upside potential.
The outlook for YMAG hinges on its ability to generate sustainable option income while managing the trade-off between yield and capital appreciation. Key risks include high expense ratios, underperformance during strong bull markets, and dependence on volatility premiums. Institutional interest appears mixed, with the fund's appeal concentrated among income-focused investors seeking Magnificent Seven exposure with enhanced yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
